Nexentis Technologies Inc. NXTS

Leading computational chemistry expert to advise MitoCareX as it expands its in silico drug-discovery capabilities Ness Ziona, Israel, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that Prof. Dan T. Major has joined the Scientific Advisory Board (“SAB”) of its wholly owned subsidiary, MitoCa

Evaluation of additional commercially available approaches for obtaining proteins is intended to enhance access to research materials, increase research flexibility and support the advancement of MitoCareX’s future in-vitro drug discovery programs Ness Ziona, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. , (NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that its wholly-owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), a drug discovery company, is evaluatin

Following its broad structural analysis of the human SLC transport protein family, MitoCareX advances from a pool of candidates to a prioritized target, reflecting continued execution of its MITOLINE®-driven discovery strategy Ness Ziona, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced

MitoCareX Bio completes comprehensive SLC transport protein analysis to support discovery of small molecules for hard-to-treat cancers and inflammatory metabolic diseases and enters an AI-driven small-molecule discovery initiative with Boltz Ness Ziona, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, h

Nexentis Technologies Inc. (NASDAQ:NXTS) shares advanced 10% on Monday after the company announced the partial monetisation of its investment in the Melz solar project in Germany, based on a project valuation of US$14.

Neve Yarak, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced the signing of an Addendum to the Loan and Partnership Agreement, together with Solterra Renewable Energy Ltd. (“Solterra”) and the other lenders, for its Melz solar PV project in Germany. The Addendum follows a share purchase agreement unde

Nexentis Technologies (NXTS) said Monday its subsidiary, MitoCareX Bio, has entered into an engageme

MITOLINE®-Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets Neve Yarak, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), h

Ness Ziona, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), today reported that it has completed a broad structural analysis of human SLC (Solute Carrier) transport proteins as part of its ongoing efforts to expand and refine its sma

Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its first drug discovery milestone since its acquisition by Nexentis: the generation of an optimized hit molecule with substantially improved pharma

MITOLINE®-Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development Neve Yarak, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its firs

Neve Yarak, Israel, May 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS), (“Nexentis” or the “Company”), a drug discovery company that is also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), has received official trademark registration from the United States Patent and Trademark Office (USPTO) for its proprietary algorithm platform, MITOLINE™. MITOLINE™ is Mi

Visit Nexentis at: www.nexentistech.com Neve Yarak, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS), (“Nexentis” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, is proud to announce the launch of its new corporate website at www.nexentistech.com. This digital milestone follows the company's recent rebranding from N2OFF, Inc., and underscores its commitment to advancin